Disease · MONDO_0005095

spondyloarthropathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. spondyloarthropathy. Diseases, record MONDO_0005095. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005095

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: spondyloarthropathy; Open Targets
Open Targets ID: MONDO_0005095; Open Targets
Other names: Disorder of joint of spine, Disorder of joint of spine (disorder), JOINT DIS NOS-OTH JT, OA - Osteoarthritis of spine, OA - Osteoarthritis of the spine, Osteoarthritis of spine, SPONDYLOS NOS W/O MYELOP, Spondarthropathy, Spondylarthropathies, Spondylarthropathy, Spondylarthrosis, Spondylarthrosis NOS, Spondyloarthropathy (disorder), Spondylosis, Spondylosis (disorder), Spondylosis of unspecified site without mention of myelopathy, Spondylosis, NOS, Unspecified joint disorder of other specified sites, seronegative spondyloarthropathy, spondyloarthritis; Open Targets
Disease Ontology: DOID:1123; Disease Ontology
NCI Thesaurus: C116778; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 7 drugs, from DailyMed and EMA Human Drugs; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ETANERCEPT	CHEMBL1201572	Protein	Approval	EMA Human Drugs	5	4	4	Drugs and targets
SECUKINUMAB	CHEMBL1743068	Antibody	Approval	DailyMed	3	2	2	Drugs and targets
FILGOTINIB	CHEMBL3301607	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
GOLIMUMAB	CHEMBL1201833	Antibody	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
TOFACITINIB	CHEMBL221959	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TNF	Tumor necrosis factor	4	TNF-alpha inhibitor	Approval	https://conductscience.org/library/genes/7124	Drugs and targets
JAK1	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Phase 3	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Phase 3	https://conductscience.org/library/genes/3718	Drugs and targets
TYK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor	Phase 3	https://conductscience.org/library/genes/7297	Drugs and targets
IL17A	Interleukin-17A	1	Interleukin 17A inhibitor	Approval	https://conductscience.org/library/genes/3605	Drugs and targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04507776	Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel		763	2021-10-04	Spondyloarthrosis	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT05785611	A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis	Phase 3	495		Axial Spondyloarthritis	FILGOTINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01610947	Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity	Not applicable	398		Spondyloarthritis	ADALIMUMAB, ETANERCEPT, GOLIMUMAB, INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03445845	Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis	Phase 4	300		Axial Spondyloarthritis	SECUKINUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05431283	Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy		100		Ulcerative Colitis, Spondyloarthropathy	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT03033095	Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers	Not applicable	50		Spondylitis, Ankylosing	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT03561649	Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA	Not applicable	50		Spondylitis, Ankylosing	ADALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00678782	Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis	Phase 2	31		Persistent Knee Joint Synovitis	ETANERCEPT	Open Targets' reading of its record	ClinicalTrials.gov
NCT00591201	Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies	Phase 2/3	26		Spondylarthropathies	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03358134	Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis	Phase 3	20		Spondylarthropathies	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41864490	RESULT	1	PubMed
41039829	DERIVED	1	PubMed
39260856	DERIVED	1	PubMed
36178583	DERIVED	1	PubMed
22867975	DERIVED	1	PubMed
22751595	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005095

GET https://conductscience.org/api/diseases/v1/MONDO_0005095/drugs

API reference For AI assistants